New Delhi: Swiss firm Ferring Pharmaceuticals plans to invest an additional Rs 5 00 crore in expanding the manufacturing of gastrointestinal (GI) drugs in India over the next three years. The company has pumped Rs 500 crore into an active pharmaceutical ingredient (API) facility and an R&D centre in India over the last five years.
Fierce Pharma looks at how much value 11 Big Pharmas have extracted from their new drug launches over the past five years.
Singapore: Indian drug giant Torrent Pharma has acquired a portfolio of generic drugs from Swiss pharma company Novartis. The details of the generic drugs are not known. As per reports, the deal is undergoing some review with the Competition Commission of India (CCI)
NEW DELHI: The United States Food and Drug Administration (US FDA) has granted Indian drug maker LupinBSE -0.14 % final approval to market a generic version of Swiss pharmaceutical giant Novartis’ tobramycin inhalation solution ‘Tobi’.
Industry watchers already have high expectations for Novartis' ($NVS) Cosentyx. But the company's execs think the drug--armed with two new approvals in quickly expanding markets--is on pace to exceed them in 2016.
Remember the days when drugmakers could raise prices without sparking political pushback? Novartis ($NVS) CEO Joe Jimenez does--and he says they're not coming back.
Swiss pharma giant Novartis ($NVS) is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines.